Introduction

Researchers at the University of Houston (UH), together with Baylor College of Medicine, have made a significant breakthrough in developing innovative microfluidic devices aimed at treating hyperleukocytosis in pediatric patients, a dangerous condition characterized by an alarming increase in white blood cells, often linked to leukemia.

Understanding Leukemia

Leukemia, known as the most prevalent cancer among children, affects approximately 5 out of every 100,000 kids in the United States annually. Worryingly, around 20-30% of children diagnosed with acute leukemia develop hyperleukocytosis, which can lead to life-threatening complications such as organ dysfunction and severe infections.

Current Treatment Challenges

While chemotherapy remains the cornerstone treatment for acute leukemia, leukapheresis offers a promising alternative for those requiring urgent intervention to lower their perilously high white blood cell counts. This procedure utilizes a large machine to separate white blood cells from the rest of the blood, which is subsequently reintroduced into the patient.

Risks of Existing Machines

However, existing leukapheresis machines pose risks, especially for young patients, due to:

High Extracorporeal Volume (ECV)